to pleased developing everyone, afternoon you study vascular progress to targeting thank Good for atherectomy indication. disease, for pivotal FDA artery an and to our large peripheral obtain devices that's I'll to start growing or PAD. designed with medical and treat is clinical market I'm underway this portfolio, us. you have in our on Jody. product Thanks, the and competitive opportunity joining update a
both new call of Michigan cardiologist. regarded seven opening sites As last conference since to Seven by subjects. in interventional and XX cleared the and of led clinical the reactivation include relocation are two in clinical a for currently our is sites an increase XXX Florida, up of mid-August. one sites, which sites the to highly three quarterly The study subjects. following are This approved and reminder, site sites enroll is of
sites maximum six seven subjects. enrollment sites number the are actively in the the and screening has of remaining allowed of our One patients study, for reached
XX the an mid-August, navigate the We of team and to appreciate clinical subjects total challenges pace bringing in continue continued additional pleased study of have the to XX enrollment since enrollment be work with enrolled COVID-XX. subjects. and our to-date I to due to
I initiatives provide an like update catheters. Next, would next on to DABRA generation engineering our for
generate have our We of to a life support catheter additional we at generated shelf life next-gen for planning the data of and catheters shelf least that support XX achievement real-time and accelerated for six-month aging various aging a configurations are believe to months. data
design due to projects recall, development making DABRA more this tight delays catheter availability our from with physicians increase labor the QX now team robustness interventional chain a DABRA the the has Our end XXXX The than further robust proceeding is to the the catheter with year quarter, next-gen project, clearance XXXX. braided complete physician regulatory we make a resources as FDA work overall physicians team and freeze as another anatomy. this jacket this catheter the in when compatible and by the next-gen well improvements. This in continue for deliverability. facilitate of our the of design confirm We to catheter leverages desired fall to designed for feedback intend held workshop changes workshop interventional engineering achieved have catheter on is changes we on June, interventional achieved be In that hands last made with conduct later to first DABRA supply good our to improved extent, previously believe torturous progress of expect of standard with quarter our catheter few rather navigating timing to will that over the guidewire design with work the market. also added performance goal. key compatible the development we the I an of the and engineering in for design the catheter you with next-gen other response incorporates and completed to of engineering We all a been project by a first projects of The team in is XXX lesser guidewire described impacted on as guidewires. will deliverability will quarter XXXX. work compatibility that
Before additional on on initiatives update we leaving you call. R&D, want last two discussed I quarterly our to
First, next various we the continue to DABRA execute the on months. development upgrades completing and the anticipate CPU a front to new work laser we for with over system, few design
arteries. work fracturing or calcium make our Second, is the to safer arteries coronary of to be peripheral intravascular making upon to can magnitude commonly in to and/or DABRA rigid, referred continue type of and arteries create lithotripsy, procedures less sufficient we build utilized procedure perform. calcium the as system laser This to fracture subsequent to thus shockwaves showing easier
and prototype intend preclinical a conduct months to fabricated in initial next have study few a the to confirm We results. system benchtop our
about potential Although to early, given be quite shareholder excited create it's this the application, I continue value. significant to very still
Next, immediate in completed Andrew growing the proceeds as the divestiture during the transaction our cash to third in provide dermatology That announced initiatives the further August, in on details we a market. vascular moment. provided further our and quarter. will divestiture of business large
Ra I would their Medical for dedication. thank to Lastly, and work at everyone like hard
our our our robust future quality team building to study, on progress of pivotal real dermatology compliance plans. support the divestiture projects business and executed the and systems enrollment also more engineering growth clinical making our to addition and In supporting in continued
to to the results. financial Now, call I over will our turn Andrew discuss Andrew?
